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PURPOSE: This study investigated the association between background parenchymal enhancement (BPE) and
pathologic response to neoadjuvant chemotherapy (NAC). METHODS: A total of 46 patients diagnosed with invasive
breast cancerwere analyzed. Each patient had threemagnetic resonance imaging (MRI) studies, one pre-treatment and
two follow-up (F/U)MRI studies. BPEwasmeasured as the averaged enhancement of thewhole fibroglandular tissues.
The pre-treatment BPE and the changes in the F/U MRI were compared between patients achieving pathologic
complete response (pCR) versus those not. Subgroup analyses based on age, estrogen receptor (ER), and human
epidermal growth factor receptor 2 (HER2) status of their cancers were also performed. RESULTS: The pre-treatment
BPEwas higher in the pCR group than that in the non-pCR group. Compared to baseline, BPE at F/U-1 was significantly
decreased in the pCR group but not in the non-pCR group. In subgroup analysis based on age, these results were seen
only in the younger group (b55 years old), not in the older group (≥55 years old). Older patients had a significantly lower
pre-treatment BPE than younger patients. In analysis based onmolecular biomarkers, a significantly decreased BPE at
F/U-1 was only found in the ER-negative pCR group but not in the non-pCR, nor in the ER-positive groups.
CONCLUSIONS: A higher pre-treatment BPE showing a significant decrease early after starting NAC was related to
pCR in pre/peri-menopausal patients.
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Dynamic contrast-enhanced (DCE) magnetic resonance imaging
(MRI) is widely used for the diagnosis of breast cancer. The amount
of contrast agents that can reach the normal fibroglandular breast
tissue is an indicator of blood perfusion to the normal tissue, referred
to as background parenchymal enhancement (BPE), which can be
evaluated qualitatively [1,2] or measured quantitatively [3]. Previous
studies have demonstrated that BPE is affected by age, physiologic
hormonal status, and hormonal therapy [4–6]. It was noted that BPE
in pre-menopausal women is altered over the women’s menstrual
cycle [7,8].
Most published studies about BPE focused on the diseased breast
harboring breast cancer. It was found that BPE may affect the
diagnostic performance of breast MRI [9,10]. Because of its clinical
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the recent updates and revision of The Breast Imaging Reporting and
Data System (BI-RADS) breast MRI lexicon [11]. Several studies also
noted that BPE surrounding primary breast tumors was associated with
response to neoadjuvant chemotherapy (NAC) and prognosis [12], as
well as with recurrence-free survival in patients with ductal carcinoma
in situ after breast conservation surgery [13]. However, because of the
presence of cancer, the measurement of BPE in the diseased breast will be
strongly dependent on the location where the measurement was made
from or the placement of region of interest (ROI).
As most DCE-MRI studies were performed bilaterally on breast
cancer patients, the BPE in the contralateral normal breast could be
measured, and on the basis of breast symmetry, the measured BPE in
this way could reflect the normal tissue enhancements in the diseased
breast. A recent study comparing the difference of BPE in the normal
breasts between pre-menopausal and post-menopausal women found
that BPE was higher in pre-menopausal than in post-menopausal
women, and a decreased BPE after receiving NAC was found in
pre-menopausal, not in post-menopausal, women [14]. These results
suggested that the difference was most likely coming from ovarian
function and the suppression due to chemotherapy [14]. Since the BPE
is related to blood perfusion (thus affecting delivery of therapeutic agent)
and likely ovarian function (thus affecting the hormone level), it may
also affect the treatment response of breast cancer to NAC. So far, there
has been no report to investigate this relationship yet.
In the present study, we measured BPE in the contralateral normal
breasts of NAC patients who achieved pathologic complete response
(pCR) and those not achieving pCR (non-pCR). The pre-treatment
BPE and the changes during NAC between the pCR and non-pCR
groups were compared. In addition, we performed subgroup analysis
by separating patients based on age, the estrogen receptor (ER), and
human epidermal growth factor receptor 2 (HER2) of their cancers.
The BPE between patients with ER-positive and ER-negative cancers
and that between patients with HER2-positive and HER2-negative
cancers were also compared.
Materials and Methods
Subjects
The study is a retrospective analysis of prospectively enrolled breast
cancer patients who were elected to receive NAC treatment before
surgery from 2002 to 2006. The study was approved by the Institutional
Review Board and was The Health Insurance Portability and
Accountability Act (HIPAA) compliant. All participants gave written
informed consent. A total of 52 subjects who had one pre-treatment
baseline MRI and at least two follow-up (F/U) MRIs while undergoing
NAC regimen and received surgery after NAC were identified. Six
patients were excluded from the analysis because of the following reasons:
patients with contralateral breast lesions, patients with extremely fatty
breast (b5% breast density as measured inMRI), and patients with poor
MR image quality in any of their three MRIs. Of remaining 46 subjects,
40 had invasive ductal cancer (IDC), 5 had infiltrating lobular cancer
(ILC), and one had mixed IDC and ILC. The age of patients at the start
of study ranged from 31 to 77 years old [50 ± 11 (mean ± SD), median
49 years]. The one-dimensional tumor size in baselineMRI ranged from
0.5 to 9.9 cm [4.1±2.3cm (mean ± SD), median 3.4 cm].
The pathologic response was determined based on the examination
of surgical specimen after completing NAC. pCR was defined as the
absence of malignant cancer cells. Non-pCR was defined as thepresence of residual cancer cells in pathology. For subgroup analysis
based on age, patients were separated into pre/peri-menopausal (b55
years old, N = 32) and post-menopausal groups (≥55 years old, N =
14). For the whole group, and each age and biomarker subgroup
(ER-positive cancer, ER-negative cancer, HER2 receptor–positive
cancer, and HER2 receptor–negative cancer), BPE in patients of the
pCR and non-pCR groups were compared.
NAC Treatment Protocol
The chemo-regimen used at our institution from 2002 to 2006
consisted of two to four cycles of dose-dense AC (doxorubicin and
cyclophosphamide, one cycle every 2 weeks) followed by taxane regimen
(TCa ± H, paclitaxel and carboplatin with Herceptin for HER2/
neu-positive patients). After the patient received two cycles of AC, based
on clinical examination and ultrasound findings, the oncologist
determined the response and decided whether she should go on to
receive additional two cycles of AC (if responding well) or be switched to
the second regimen (if not). The first F/U-MRI was performed after one
cycle (N = 19) or two cycles (N = 27) of AC. The second F/U-MRI was
performed after receiving four cycles of AC (N = 25) or after receiving two
cycles AC plus three weekly second-line taxane-based regimen (N = 21).
MRI Study Protocol
All MRI studies were performed on a 1.5-T Philips Eclipse MR
scanner (Philips Medical System, Best, Netherlands) using a
dedicated bilateral breast coil with the patient in the prone position.
The DCE-MRI was acquired using a three dimensional (3D) gradient
echo pulse sequence (RF-FAST) with repetition time (TR)/echo time
(TE) = 10/3.6 milliseconds, flip-angle = 20°, 32 bilateral-axial
partitions covering both breasts with 4-mm thickness each, field of
view (FOV) = 32 to 38 cm, and acquisition matrix = 256 × 128.
Sixteen dynamic frames (repetitions) were prescribed for the
DCE-MRI, each of which was acquired in 42 seconds. The contrast
agent [Omniscan (0.1 mmol/kg); Nycomed-Amersham, Princeton,
NJ] was injected manually at start of the fifth frame acquisition and
then followed by 10-ml saline flush. All MR images were transferred
to a personal computer for post-processing.
Fibroglandular Tissue Segmentation
To avoid the bias coming from the arbitrary ROI selection, we
applied a computer-based segmentation algorithm to segment the
entire fibroglandular tissues contained in the normal breast using the
pre-contrast images of DCE-MRI [15]. Briefly, the segmentation
procedures consisted of the following steps: 1) an initial segmentation
of the breast region based on V-shape cut using three user-entered
anatomic landmarks (thoracic spine and bilateral pectoral muscles);
2) a fuzzy c-means (FCM)–based segmentation algorithm with the
B-spline curve fitting to obtain the chest wall boundary; 3) exclusion
of skin along the breast boundary by dynamic searching algorithm;
4) removal of non-uniformity in image intensity through bias field
correction based on the adaptive FCM; 5) differentiation of the
fibroglandular tissue from the surrounding fatty tissue using an
FCM-based clustering method. An experienced operator performed
the segmentation for all subjects included in this study.
Measurement of BPE
BPE was defined as the average of the contrast enhancements
measured from all pixels contained with the segmented fibroglandular
tissue. BPE indicated a percent (%) increase of enhancement after
Table 2. BPE (Mean ± SD, %) Stratified Based on pCR and Non-pCR
Baseline MRI F/U-1 MRI F/U-2 MRI
pCR (N = 24) 19.4±13.4 15.6±9.0 † 12.5±7.0*
Non-pCR (N = 22) 15.8±10.9 16.2±15.7 12.9±9.3*
† Significantly lower at F/U-1 compared to the baseline value (P = .02).
* Significantly lower at F/U-2 compared to the baseline value (P = .006 in the pCR group and P = .04 in
the non-pCR group).
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Senh,i denoted the fibro-pixel–averaged signal intensity from the ith
enhanced image and Snon-enh denoted the averaged signal intensity of
the same fibro-pixels from the four pre-contrast imaging sets). The
calculation was done for each of the 12 post-contrast frames acquired
during the 7-minute DCE period, and a mean BPE for each MRI
study was obtained by averaging over all 12 time points for
subsequent analysis (i.e., BPE = ∑BPEi/12).
Statistical Analyses
Two-tailed t test was used to assess the statistical significance of
observed group differences. The significance level in all statistical tests
was set at P b .05. The statistical analyses were carried out using the
Matlab Statistics Toolbox.
Results
Clinicopathologic Characteristics
The clinicopathologic characteristics of pCR and non-pCR groups
were listed in Table 1. Twenty-four patients achieved pCR, and 22
patients had residual disease (non-pCR). Of the 46 patients, 25 had
(ER) positive cancer and 21 had ER-negative cancer; 25 had HER2
receptor–positive cancer and 20 had HER2 receptor–negative cancer.
The HER2 information was not available for one patient. It was
noted that all the six patients with lobular component had residual
cancer following the therapy.
BPE in pCR and Non-pCR Groups
Of the 46 patients, 24 (52%) achieved pCR. This very high pCR
response rate was similar to the previous literature reports [16].
The BPEs in the contralateral normal breast measured in the baseline,
F/U-1, and F/U-2 MRI studies in the pCR and non-pCR groups are
listed in Table 2. In the pCR group, compared to the baseline BPE
value (mean 19.4%), the BPE at F/U-1 after 2 to 4 weeks of
chemotherapy was decreased (15.6%, P = .02) and further decreased
at F/U-2 (12.5%, P = .006). In the non-pCR group, the BPE was not
decreased at F/U-1 but became significantly decreased at F/U-2 (only
marginally with P = .04). When comparing the baseline BPE, it was
higher in the pCR group than in the non-pCR group (19.4% vs
15.8%, P = .31) but not reaching the significance level. If the
contralateral normal breast is considered the mirror of the diseased
breast without cancer, the results suggest that a higher normal tissue
BPE before treatment that shows reduction after chemotherapy is
more likely to achieve pCR.
BPE in Pre-Menopausal and Post-Menopausal Groups
The summary results are listed in Table 3. The younger group
(b55 years old) had 32 patients, 19 achieving pCR and 13 not. TheTable 1. Clinicopathologic Information of the pCR and Non-pCR Groups
pCR (N = 24) Non-pCR (N = 22)
Mean age (years old) 47.4 52.9
IDC 24 16
ILC 0 5
IDC/ILC 0 1
Baseline tumor size (cm) 4.3 3.9
ER-positive 9 16
ER-negative 15 6
HER2-positive 16 9
HER2-negative 8 12older group (≥55 years old) had 14 patients, including 5 patients with
pCR and 9 patients with non-PCR. Younger patients had a higher
pCR rate (59% vs 36%). Similar to a study reported before [14], the
younger patient group had a significantly higher BPE compared to the
older patient group (20.2% vs 12.0%, P = .007). As the whole group,
the younger patients showed a slightly decreased BPE after the start of
chemotherapy at F/U-1 (18.0%) compared to the baseline value
(20.2%, P = .19, not significant), and the BPE was further decreased
at F/U-2 (12.9%, P = .0001). After stratifying patients to the pCR
and non-pCR groups, it was seen that pCR patients had a higher
baseline BPE (21.1%), which decreased significantly at F/U-1
(16.0%, P = .01) and further decreased at F/U-2 (12.4%, P =
.003). In the non-pCR group, there was no significant change in
BPE at F/U-1 (in fact, it increased from 18.8% at baseline to 20.9%
at F/U-1), but after more chemotherapy sessions, the BPE was
decreased to 13.6% at F/U-2 (P = .01). In contrast, in the older
patient group, there was no significant change at F/U-1 or F/U-2
compared to the baseline value in any group comparison. This finding
in the post-menopausal women may be related to small patient
number as well as the low BPE at baseline, which leaves no room for
further decrease.
BPE in ER-Positive and ER-Negative Groups
We had 25 ER-positive and 21 ER-negative patients. The
summary results are listed in Table 4. In ER-positive group, 9
achieved pCR (36%) and 16 not; in the ER-negative group, 15
achieved pCR (71%) and 6 not. The pCR rate result was consistent
with the general knowledge that ER-negative patients have a better
response to chemotherapy. The baseline BPE in the ER-negative
group was 19.2%, which was higher compared to the baseline BPE in
the ER-positive group (16.4%, P = .45, not significant). The BPE
was significantly decreased at F/U-1 and F/U-2 only in the pCR
group of ER-negative patients. The mean BPE of this subgroup was
20.3% at baseline, which decreased to 16.5% (P = .03) and further
decreased to 12.5% at F/U-2 (P = .01). Figure 1 shows a
pre-menopausal woman with ER-negative cancer achieving pCRTable 3. BPE (Mean ± SD, %) Stratified Based on Age (b55 years old and ≥55 years old) and the
pCR and Non-pCR Cases in Each Age Group
Baseline MRI F/U-1 MRI F/U-2 MRI
Younger than 55 years old (N = 32) 20.2±13.5 # 18.0±14.0 # 12.9±8.9*
pCR (N = 19) 21.1 ± 14.4 16.0 ± 10.0 † 12.4 ± 7.1*
Non-pCR (N = 13) 18.8 ± 12.4 20.9 ± 18.5 13.6 ± 11.3*
Older or equal to 55 years old (N = 14) 12.0±6.2 11.0±6.0 12.1±6.1
pCR (N = 5) 13.2 ± 6.3 14.0 ± 3.3 12.7 ± 7.5
Non-pCR (N = 9) 11.4 ± 6.4 9.4 ± 6.6 11.8 ± 5.7
† Significantly lower at F/U-1 compared to the baseline value (P = .01 for the b55 year old pCR group).
* Significantly lower at F/U-2 compared to the baseline value (P = .0001 for patientsb55 years old,P = .003 for the
b55 year old pCR group, and P = .01 for the b55 year old non-pCR group).
# Significant difference between the b55 year old and ≥55 year old groups (P = .007 for baseline MRI and
P = .02 for F/U-1 MRI).
Table 4. BPE (Mean ± SD, %) Stratified Based on ER Status and the pCR and Non-pCR Cases in
Each ER Group
Baseline MRI F/U-1 MRI F/U-2 MRI
ER-positive (N = 25) 16.4 ± 11.7 15.5 ± 13.7 12.9 ± 9.4
pCR (N = 9) 18.1 ± 10.1 13.9 ± 4.8 12.4 ± 7.0
Non-pCR (N = 16) 15.5 ± 12.4 16.4 ± 16.8 13.1 ± 10.6
ER-negative (N = 21) 19.2 ± 13.1 16.2 ± 11.3 12.4 ± 6.4*
pCR (N = 15) 20.3 ± 15.1 16.5 ± 10.7 † 12.5 ± 7.0*
Non-pCR (N = 6) 16.5 ± 5.7 15.5 ± 13.6 12.2 ± 4.8
† Significantly lower at F/U-1 compared to the baseline value (P = .03 in ER-negative pCR group).
* Significantly lower at F/U-2 compared to the baseline value (P = .004 for the entire ER-negative group
and P = .01 for the ER-negative pCR group).
Figure 2. Contrast-enhanced subtraction images of a 56-year-old
woman with non-pCR after NAC. Before NAC, a 3-cm ER-positive
and HER2-negative IDC in the left breast was noted. Upper panel:
baseline MRI; middle panel: FU-1 MRI (after two AC); lower panel:
FU-2 MRI (after two AC plus three AbCaH). Note that the
background enhancement in the fibroglandular tissue of the right
breast throughout the three MRI studies was scarce.
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decreased in the F/U-1 and further decreased in the F/U-2. In
contrast to Figure 1, Figure 2 shows a post-menopausal woman with
non-pCR after NAC. Since BPE is low in all three studies of
pre-treatment and post-treatment MRIs, the decrease of BPE in the
F/U-1 and the F/U-2 was not obvious.
BPE in HER2-Positive and HER2-Negative Groups
The summary results are listed in Table 5. Of 25 HER2-positive
patients, 16 achieved pCR (64%) and 9 not; of 20 HER2-negative
patients, 8 achieved pCR (40%) and 12 not. Since HER2-positive
patients received the targeted therapy trastuzumab, it is well known
that they have a higher pCR rate. The baseline BPE in HER2-positive
group was 19.7%, which was higher than that in the HER2-negative
group (15.2%, P = .24, not significant). The BPEs in both
HER2-positive and HER2-negative groups were not significantly
decreased at F/U-1 but became significant at F/U-2. Interestingly, in
either HER2-positive or HER2-negative group, the BPE was
decreased at F/U-1 in both pCR groups and remained at a
comparable baseline level in both non-pCR groups. Therefore, theFigure 1. A 32-year-old woman with pCR after NAC. Before NAC, a 9.1-cm triple negative IDC in the right breast was noted. Upper panel:
baseline MRI; middle panel: FU-1 MRI (after two AC); lower panel: FU-2 MRI (after four AC). The left and middle columns are two
continuous subtraction images. The right column is the maximal intensity projection image. Note the strong background enhancement in
the fibroglandular tissue of the left breast in the baseline MRI. The enhancement decreases in the FU-1 MRI and further decreases
remarkably in the FU-2 MRI. The BPE was 60.0%, 46.3%, and 30.0% in baseline, F/U-I, and F/U-2 MRI, respectively.
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quite similar, different from those reported above in age comparison
or ER status comparison.
Discussion
In this study, wemeasured the pre-treatment BPE, as well as the changes
shortly after the start of chemotherapy (2 to 4 weeks) and at mid time
point during the course of NAC (after 8 weeks). For the comparison of
BPE, the qualitative assessment of mild, moderate, or severe BPE using
visual inspection was not applicable [1,2,5,9,10]. In addition, to
facilitate a fair comparison, the assessment of BPE from an arbitrarily
definedROI or a hot spot was not optimal. Since a computer algorithm–
based method to segment the entire fibroglandular tissue within the
whole breast has been developed [15], this method could be used to well
define the ROI for measuring themean BPE in a breast by averaging the
contrast enhancements from all fibroglandular tissue voxels. It has been
reported that the contrast enhancement in normal tissues surrounding
the cancer was associated with treatment response and prognosis
[12,13], but since the value will be strongly dependent on where the
measurement is taken from, it cannot serve as a reliable prognostic
predictor. The BPEmeasured from the normal tissue of the contralateral
breast, especially using a computer algorithm–based segmentation
software, can provide an unbiased method allowing us to investigate the
relationship between normal tissue enhancements and pathologic
response of breast cancer to NAC.
Table 1 summarizes the major findings in this work. Patients
achieving pCR had a higher pre-treatment BPE than that in the
non-pCR group. In the pCR group, BPE showed a significant
decrease at F/U-1 and further decrease at F/U-2. In contrast, in the
non-pCR group, BPE in F/U-1 increased slightly and then showed a
significant decrease at F/U-2. These results suggested that patients
with a higher pre-treatment BPE that showed a significant decrease at
early times after starting NAC were more likely to achieve pCR. This
finding obtained in normal tissues is consistent with results found in
tumors. Studies have shown that tumors with a higher pretreatment
enhancement [17] or having a greater decrease of enhancement after
chemotherapy [17–20] tend to have a better response to the
treatment. One possible explanation is that since chemotherapy
agents are delivered through blood perfusion, a higher BPE in normal
breast tissues may allow more delivery of therapeutic agents into the
breast leading to a better response. Since chemotherapy exerts effects
on tumor vasculature by loss of pro-angiogenic support secondary to
tumor cell kill and also directly on endothelial cell function [21], a
higher delivery of chemotherapy agents into the normal tissue will
lead to more severe damage of vessels and a greater decrease in BPE.Table 5. BPE (mean ± SD, %) Stratified Based on HER2 Status and the pCR and Non-pCR Cases
in Each HER2 Group
Baseline MRI F/U-1 MRI F/U-2 MRI
HER2-positive (N = 25) 19.7 ± 12.3 17.1 ± 14.1 13.9 ± 9.3
pCR (N = 16) 19.5 ± 11.7 15.3 ± 6.6 13.0 ± 6.5
Non-pCR (N = 9) 20.0 ± 14.2 20.4 ± 22.3 15.4 ± 13.3
HER2-negative (N = 20) 15.2 ± 12.4 14.0 ± 10.6 10.9 ± 6.3
pCR (N = 8) 19.4 ± 17.4 16.1 ± 13.1 11.4 ± 8.3
Non-pCR (N = 12) 12.4 ± 7.1 12.6 ± 8.9 10.6 ± 5.0
* Significantly lower at F/U-2 compared to the baseline value (P = .007 for theHER2-positive group,P = .04 for
the HER2-positive pCR group, P = .04 for the HER2-positive non-pCR group, and P = .05 for the
HER2-negative group).We also performed subgroup analyses by separating patients based on
the age and the ER and HER2 biomarker of their cancers. Previous
studies have shown that BPE is affected by the menopausal status
[1,4,5,7,8].We used the cutoff age of 55 to ensure that women ≥55 years
old were indeed post-menopausal. As expected, the pre-treatment
baseline BPE was significantly higher in the younger group compared to
the older group (20.2% vs 12.0%, P = .007). In previous studies
analyzing the change of breast density and BPE after NAC with age, a
significant decrease was only found in the pre-menopausal, not in the
post-menopausal, women [14]; therefore, one possible explanation was
attributed to chemotherapy-induced ovarian suppression [22]. Com-
paring with Table 2, it can be found that the major findings in Table 1
weremainly driven by the results in pre-menopausal women. In addition
to the direct damage of vessels in normal tissues by chemotherapy,
another possible reason explaining the decreased BPE after NAC is the
loss of tissue proliferation due to decreased hormones coming from
ovarian suppression. This side effect of chemotherapy (i.e., ovarian
suppression) is known to have a positive prognostic value in the
pre-menopausal women [22–24].
Tables 3 and 4 show the subgroup analysis results stratified based on
the ER and HER2 status of patient’s cancer. The pCR rate was higher in
ER-negative than in ER-positive and higher in HER2-postive than in
HER2-negative groups in our study, which was consistent with literature
reports, e.g., results from seven prospective randomized trials consisting of
6377 patients [25]. The measurement of BPE from the contralateral
normal breast was assumed to reflect the enhancement in normal breast
tissues surrounding the cancer in the diseased breast. The contralateral
BPE was higher in ER-negative (19.2%) than in ER-positive patients
(16.4%), and higher in HER2-positive (19.7%) than in HER2-negative
(15.2%) patients but both did not reach the significant level. Since
we have approximately the same number of pre-menopausal and
post-menopausal patients in each subgroup, the observed result was not
mediated through age. The contrast enhancements were known to be
higher in ER-negative than in ER-positive cancers [26–28], also higher in
HER2-positive than inHER2-negative cancers [28,29], and interestingly
in our study, we found a similar trend in normal tissues. There has been
no study yet to compare the BPE with the type of cancer that was
developed, and this warrants further investigation. Such results may
provide useful information for chemoprevention.
Table 3 also shows the comparison between pCR and non-pCR
patients in the respective ER-positive and ER-negative groups. Patients
with ER-negative cancer who achieved pCRhad a significant reduction of
BPE at F/U-1 compared to the baseline value, while the effect was not
noted in the non-pCR patients or in the ER-positive patient group. It was
also noted that the ER-negative pCR group had the highest averaged
baseline BPE (20.3%) compared to other subgroups. The high BPEmay
facilitatemore delivery of chemotherapy agents into the breast resulting in
the early significant reduction of BPE at F/U-1 and subsequently leading
to a better response and achieving pCR. Table 4 shows that the BPE
results in HER2-positive and HER2-negative groups are pretty similar,
both showing a significant decrease at F/U-2 and no difference between
pCR and non-pCR patients.
This study had limitations. The number of subjects included in this
study was small. The protocol of the MR images acquired in this study
was done using a 1.5 T-MR scanner, which was designed to have a high
temporal resolution and had to sacrifice the spatial resolution a bit. The
spatial resolution (matrix size = 256 × 128) thus was lower, compared to
the current standard emphasizing on high spatial resolution. In this study,
we defined women b55 years old as the pre/peri-menopausal group and
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general observation that natural menopause may start from the age of 45
years old andmay possibly last for years. Thus, we used 55 years old as the
cutoff to ensure that women older than 55 years old should have reached
their stable menopause stage. Nevertheless, the division is arbitrary and
thus was not 100% correct.
In summary, we have demonstrated the potential value of BPE
measured from the contralateral normal breast for predicting NAC
response. Using the contrast enhancement averaged over all fibroglandular
tissues segmented in the whole breast could reflect the normal tissues
surrounding the cancer in the diseased breast and provide an unbiased
parameter to serve as a predictive or prognostic indicator.We found that
patients with a higher pre-treatment BPE who showed a significant
decrease at early times after the start of chemotherapyweremore likely to
achieve pCR. In subgroup analysis, we further showed that this finding
was mainly applicable to younger patients and to patients with
ER-negative breast cancer. A higher BPE to normal tissues would allow
more delivery of therapeutic agents into the breast, which was a possible
reason leading to a better response. These findings and the role of normal
breast BPE in the management of breast cancer patients will need to be
further investigated in larger studies.
References
[1] Uematsu T, Kasami M, and Watanabe J (2012). Should breast MRI be
performed with adjustment for the phase in patients' menstrual cycle?
Correlation between mammographic density, age, and background enhancement
on breast MRI without adjusting for the phase in patients' menstrual cycle. Eur J
Radiol 81, 1539–1542.
[2] Jansen SA, Lin VC, Giger ML, Li H, Karczmar GS, and Newstead GM (2011).
Normal parenchymal enhancement patterns in women undergoing MR
screening of the breast. Eur Radiol 21, 1374–1382.
[3] Klifa C, Suzuki S, Aliu S, Singer L, Wilmes L, Newitt D, Joe B, and Hylton N
(2011). Quantification of background enhancement in breast magnetic
resonance imaging. J Magn Reson Imaging 33, 1229–1234.
[4] Muller-Schimpfle M, Ohmenhauser K, Stoll P, Dietz K, and Claussen CD
(1997). Menstrual cycle and age: influence on parenchymal contrast medium
enhancement in MR imaging of the breast. Radiology 203, 145–149.
[5] Baltzer PA, Dietzel M, Vag T, Burmeister H, Gajda M, Camara O, Pfleiderer
SO, and Kaiser WA (2011). Clinical MR mammography: impact of hormonal
status on background enhancement and diagnostic accuracy. Röfo 183, 441–447.
[6] King V, Kaplan J, Pike MC, Liberman L, David Dershaw D, Lee CH, Brooks
JD, and Morris EA (2012). Impact of tamoxifen on amount of fibroglandular
tissue, background parenchymal enhancement, and cysts on breast magnetic
resonance imaging. Breast J 18, 527–534.
[7] Kuhl CK, Bieling HB, Gieseke J, Kreft BP, Sommer T, Lutterbey G, and Schild
HH (1997). Healthy premenopausal breast parenchyma in dynamic contras-
t-enhanced MR imaging of the breast: normal contrast medium enhancement
and cyclical-phase dependency. Radiology 203, 137–144.
[8] Delille JP, Slanetz PJ, Yeh ED, Kopans DB, and Garrido L (2005). Physiologic
changes in breast magnetic resonance imaging during the menstrual cycle:
perfusion imaging, signal enhancement, and influence of the T1 relaxation time
of breast tissue. Breast J 11, 236–241.
[9] Uematsu T, Kasami M, and Watanabe J (2011). Does the degree of background
enhancement in breast MRI affect the detection and staging of breast cancer? Eur
Radiol 21, 2261–2267.
[10] Uematsu T, Kasami M, and Watanabe J (2012). Background enhancement of
mammary glandular tissue on breast dynamic MRI: imaging features and effect
on assessment of breast cancer extent. Breast Cancer 19, 259–265.
[11] Edwards SD, Lipson JA, Ikeda DM, and Lee JM (2013). Updates and revisions
to the BI-RADS magnetic resonance imaging lexicon. Magn Reson Imaging Clin
N Am 21, 483–493.[12] Hattangadi J, Park C, Rembert J, Klifa C, Hwang J, Gibbs J, and Hylton N
(2008). Breast stromal enhancement on MRI is associated with response to
neoadjuvant chemotherapy. Am J Roentgenol 190, 1630–1636.
[13] Kim SA, Cho N, Ryu EB, Seo M, Bae MS, Chang JM, and Moon WK (2014).
Background parenchymal signal enhancement ratio at preoperative MR imaging:
association with subsequent local recurrence in patients with ductal carcinoma in
situ after breast conservation surgery. Radiology 270, 699–707.
[14] Chen JH, Yu H, Lin M, Mehta RS, and Su MY (2013). Background
parenchymal enhancement in the contralateral normal breast of patients
undergoing neoadjuvant chemotherapy measured by DCE-MRI. Magn Reson
Imaging 31, 1465–1471.
[15] Nie K, Chen JH, Chan S, ChauMK, Yu HJ, Bahri S, Tseng T, Nalcioglu O, and
Su MY (2008). Development of a quantitative method for analysis of breast
density based on three-dimensional breast MRI. Med Phys 35, 5253–5262.
[16] Chen JH, Feig B, Agrawal G, Yu H, Carpenter PM,Mehta RS, Nalcioglu O, and
Su MY (2008). MRI evaluation of pathological complete response and residual
tumors in breast cancer following neoadjuvant chemotherapy. Cancer 112,
17–26.
[17] Nagashima T, Sakakibara M, Nakamura R, Arai M, Kadowaki M, Kazama T,
Nakatani Y, Koda K, and Miyazaki M (2006). Dynamic enhanced MRI predicts
chemosensitivity in breast cancer patients. Eur J Radiol 60, 270–274.
[18] Knopp MV, Brix G, Junkermann HJ, and Sinn HP (1994). MR mammography
with pharmacokinetic mapping for monitoring of breast cancer treatment during
neoadjuvant therapy. Magn Reson Imaging Clin N Am 2, 633–658.
[19] Hayes C, Padhani AR, and Leach MO (2002). Assessing changes in tumour
vascular function using dynamic contrast-enhanced magnetic resonance imaging.
NMR Biomed 15, 154–163.
[20] Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ,
Stirling JJ, d'Arcy JA, Collins DJ, and Pittam MR, et al (2008). Early changes in
functional dynamic magnetic resonance imaging predict for pathologic response
to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 14,
6580–6589.
[21] Miller KD, Sweeney CJ, and Sledge Jr GW (2001). Redefining the target:
chemotherapeutics as antiangiogenics. J Clin Oncol 19, 1195–1206.
[22] Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L,
Atkins JN, Polikoff JA, Vogel VG, and Erban JK, et al (2009). NSABP-B30:
definitive analysis of patient outcome from a randomized trial evaluating different
schedules and combinations of adjuvant therapy containing doxorubicin,
docetaxel, and cyclophosphamide in women with operable, node positive breast
cancer. Cancer Res 69, 75 [Suppl].
[23] Pagani O, O'Neill A, Castiglione M, Gelber RD, Goldhirsch A, Rudenstam CM,
Lindtner J, Collins J, Crivellari D, and Coates A, et al (1998). Prognostic impact
of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer
patients with axillary node involvement: results of the International Breast
Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 34, 632–640.
[24] Parulekar W, Day AG, Ottaway JA, Shepherd LE, Trudeau ME, Bramwell V,
Levine M, Pritchard KI, and National Cancer Institute of Canada Clinical Trials
Group (2005). Incidence and prognostic impact of amenorrhea during adjuvant
therapy in high-risk premenopausal breast cancer: analysis of a National Cancer
Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5. J Clin
Oncol 23, 6002–6008.
[25] vonMinckwitz G, Untch M, Blohmer JU, Costa SD, EidtmannH, Fasching PA,
Gerber B, Eiermann W, Hilfrich J, and Huober J, et al (2012). Definition and
impact of pathologic complete response on prognosis after neoadjuvant
chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30,
1796–1804.
[26] KooHR,ChoN, Song IC, KimH,Chang JM, Yi A, YunBL, andMoonWK(2012).
Correlation of perfusion parameters on dynamic contrast-enhanced MRI with
prognostic factors and subtypes of breast cancers. J Magn Reson Imaging 36, 145–151.
[27] Chang YW, Kwon KH, Choi DL, Lee DW, Lee MH, Lee HK, Yang SB, Kim Y,
and Seo DY (2009). Magnetic resonance imaging of breast cancer and correlation
with prognostic factors. Acta Radiol 50, 990–998.
[28] Baltzer PA, Vag T, DietzelM, Beger S, Freiberg C, GajdaM, CamaraO, and Kaiser
WA (2010). Computer-aided interpretation of dynamic magnetic resonance
imaging reflects histopathology of invasive breast cancer.EurRadiol20, 1563–1571.
[29] Artemov D, Mori N, Ravi R, and Bhujwalla ZM (2003). Magnetic resonance
molecular imaging of the HER-2/neu receptor. Cancer Res 63, 2723–2727.
